1. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.
- Author
-
Zarei, Malek, Sahebi Vaighan, Navideh, and Ziai, Seyed Ali
- Subjects
- *
PURINERGIC receptors , *CYTOKINE release syndrome , *COVID-19 , *COVID-19 treatment , *CYTOKINE receptors , *ADULT respiratory distress syndrome , *MULTIPLE organ failure - Abstract
The coronavirus disease-19 (COVID-19), at first, was reported in Wuhan, China, and then rapidly became pandemic throughout the world. Cytokine storm syndrome (CSS) in COVID-19 patients is associated with high levels of cytokines and chemokines that cause multiple organ failure, systemic inflammation, and hemodynamic instabilities. Acute respiratory distress syndrome (ARDS), a common complication of COVID-19, is a consequence of cytokine storm. In this regard, several drugs have been being investigated to suppress this inflammatory condition. Purinergic signaling receptors comprising of P1 adenosine and P2 purinoceptors play a critical role in inflammation. Therefore, activation or inhibition of some subtypes of these kinds of receptors is most likely to be beneficial to attenuate cytokine storm. This article summarizes suggested therapeutic drugs with potential anti-inflammatory effects through purinergic receptors. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF